NuVision

What NuVision does

NuVision Biotherapies is a UK-based biotechnology company founded in 2015 as a University of Nottingham spin-out, developing and commercialising regenerative therapies for ocular surface disease. Its core offering is Omnigen, a dehydrated human amniotic membrane wound dressing produced using the proprietary, dual-patented Tereo Process, which preserves the natural barrier function of the membrane and enables room-temperature storage at 2-25°C. The product is complemented by OmniLenz, a bespoke bandage contact lens manufactured exclusively with Menicon UK that enables suture-free, 4-6 minute outpatient application of Omnigen. An extended L-range product line addresses more severe ocular injuries with 100% greater surface area, and the ROMEO Ophthalmology Registry (built with Dendrite Clinical Systems) provides a clinical data platform for outcome tracking and regulatory surveillance.

The company sells directly to NHS hospitals and private clinics in the UK, with over 160 NHS centres and 30 private hospitals supplied — including Moorfields Eye Hospital as a flagship reference account — and distributes internationally through partner networks across 12 countries in Europe, Scandinavia, and the Middle East. Manufacturing takes place at HTA-licensed clean-room facilities at MediCity in Nottingham. Revenue is generated through product sales (Omnigen and OmniLenz hardware sales), with go-to-market executed through field-based clinical product specialists (~75% travel), KOL engagement, surgical wet labs, clinical fellowship programmes, and conference participation.

NuVision is currently transitioning from an R&D-led organisation to a commercially-focused business. Following a £4.8m funding round in February 2026 led by the Midlands Engine Investment Fund II through Mercia Ventures, the company appointed Tim Precious (former EssilorLuxottica GM UK/Ireland) as CEO in May 2026 and Joanna Underhill (formerly Allergan Aesthetics Gulf, $50M business) as Non-Executive Director. Cumulative funding exceeds £5m across multiple rounds since inception, and the company is positioning for international scale-up and broader clinical indications including chronic wound care applications such as diabetic foot ulcers.

Name

NuVision

Legal name

NuVision Biotherapies Ltd

Website

https://nu-vision.co.uk

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

NuVision Biotherapies is a University of Nottingham spin-out that develops and sells Omnigen, a Tereo-processed dehydrated amniotic membrane wound dressing, and the OmniLenz bandage contact lens for suture-free ocular treatment. It supplies 160+ NHS centres and 12 international markets.

Ownership category

akta.pro rank

Product category

Ophthalmic Biotherapies

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)

akta.pro secondary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

Keywords

• Amniotic membrane therapy
• Ocular wound healing
• Ophthalmic biotherapies
• Regenerative medicine devices
• Clinical data registry

Headquarters

HQ city

Nottingham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Omnigen Product Sales: Sale of Omnigen amniotic membrane wound dressing/grafting material to NHS hospitals and private clinics. Product supplied as dry, room-temperature stable format ready for application.
2. OmniLenz Bandage Contact Lens Sales: Sale of OmniLenz bespoke bandage contact lens (manufactured exclusively by Menicon UK) used in combination with Omnigen for suture-free outpatient application.
3. International Distribution: Revenue from distribution agreements across 12 countries in Europe, Scandinavia, and Middle East.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

NuVision Biotherapies manufactures and distributes Omnigen, a dry human amniotic membrane wound dressing processed via the proprietary dual-patented Tereo Process that preserves natural barrier function and enables room-temperature storage (2–25°C). The company also sells OmniLenz, a bespoke bandage contact lens designed with Menicon UK to apply Omnigen suture-free in a 4–6 minute outpatient procedure, and operates ROMEO Ophthalmology, an online clinical registry for amniotic membrane outcomes.

Product overview

NuVision Biotherapies offers a focused portfolio of ocular surface disease treatments centered on amniotic membrane-based biotherapies. The core product is Omnigen, a patented dry human amniotic membrane wound dressing processed using the proprietary Tereo Process, which preserves natural barrier function and enables room-temperature storage. OmniLenz, a bespoke bandage contact lens, serves as the key delivery mechanism enabling suture-free, in-office application of Omnigen in 4-6 minutes. ROMEO Ophthalmology provides a clinical data registry platform for outcome tracking and research. These products work together to enable treatment across NHS hospitals, private clinics, and community optometry settings.

Differentiator

Problem solved

Functional benefit

Products and services

• Omnigen A patented dry human amniotic membrane wound dressing and grafting material derived from C-section placental donations, retaining natural barrier function to support ocular wound healing and recovery. Stored at 2–25°C and applied directly to the ocular surface. Used by ophthalmologists in NHS hospitals and private clinics.
• OmniLenz A bespoke bandage contact lens manufactured exclusively with Menicon UK to apply and hold Omnigen at the ocular surface without sutures or surgery. Enables a 4–6 minute outpatient procedure for ambulatory application of amniotic membrane treatment.
• ROMEO Ophthalmology Registry Online registry platform built with Dendrite Clinical Systems for eye care specialists to record, collate and audit anonymised procedural and clinical data specific to amniotic membrane use. Supports clinical evaluation, regulatory surveillance, research and standardisation of care.

Quantifiable outcome

• 86% of patients with refractory persistent epithelial defects had complete or partial healing in 25 days with average 1.2 applications
• +3 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Menicon UKcoreTechnology or IntegrationExclusive manufacturer of OmniLenz bespoke bandage contact lens designed specifically for NuVision to apply Omnigen without sutures or surgery.
• Dendrite Clinical SystemscoreStrategic or Co-development PartnerJoint development of ROMEO Ophthalmology registry platform for recording amniotic membrane transplantation outcomes. Dendrite provides Intellect-Web registry software.
• Aston UniversitycoreStrategic or Co-development PartnerClinical research collaboration for dry eye disease trials using Omnigen-OmniLenz. Professor James Wolffsohn leads clinical programme. Partnership for Optometry Clinical Specialist role with company-sponsored PhD opportunity.
• Kestrel OphthalmicsminorGTM or Marketing PartnerJoint surgical wet lab sponsorship for training ophthalmic surgeons on amniotic membrane application techniques.
• Medilink MidlandsminorStrategic or Co-development PartnerRegional life science association providing innovation support grants, funding for clinical fellowship programme, and networking support.
• East Midlands Academic Health Science Network (AHSN)minorStrategic or Co-development PartnerPart-funded NuVision Clinical Fellowship Programme collaborating with NHS trusts to audit amniotic membrane use and improve patient care.
• Department for International Trade (DIT)coreGTM or Marketing PartnerUK government department supporting international trade expansion; NuVision exhibited alongside DIT at Arab Health and Medica to develop distributor relationships.
• Queen Victoria Hospital NHS TrustcoreStrategic or Co-development PartnerSpecialist tertiary referral centre for complex corneal conditions; hosted NuVision Clinical Fellowship Programme; multiple clinicians presenting case studies on Omnigen use.
• Maidstone and Tunbridge Wells NHS TrustcoreStrategic or Co-development PartnerLargest specialised eye unit in South-East England serving 1 million population; collaborated on NuVision Fellowship Programme auditing amniotic membrane outcomes.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Bio-Tissue (TissueTech): Bio-Tissue markets Prokera, the most widely recognised cryopreserved amniotic membrane product for ocular surface disease, directly competing with Omnigen in the same ophthalmic clinical workflow with overlapping indications including PEDs, dry eye, and corneal ulcers.
• MTF Biologics: MTF Biologics distributes AmnioBand and other dehydrated amniotic membrane allografts used in ocular surface reconstruction and wound care, providing direct competition in both ophthalmic and broader wound healing applications.
• IOP Ophthalmics: IOP Ophthalmics markets AmbioDisk, a dehydrated amniotic membrane disc for ocular surface disease, directly comparable to Omnigen in product format and clinical use case for treating corneal and conjunctival defects.
• MiMedx: MiMedx sells dehydrated amniotic membrane products (EpiFix, AmnioFix) primarily for wound care but with ophthalmic-adjacent applications; comparable as a tissue-based regenerative therapy peer using proprietary processing of placental tissue.

Emerging players

• Celularity: Celularity develops cellular and regenerative therapies derived from postpartum placental tissue, including wound care applications; shares NuVision's biological material source and regenerative therapy positioning though with broader therapeutic scope.
• Organogenesis: Organogenesis markets regenerative medicine products including wound care biologics (Apligraf, Dermagraft), sharing the regenerative tissue therapy positioning with NuVision though focused on chronic wounds rather than ocular surface.
• Katena Products: Katena Products distributes ophthalmic surgical devices and biologics including amniotic membrane products to eye surgeons globally, partially overlapping with NuVision's distribution channel into ophthalmic surgical settings.

Broad incumbents

• Integra LifeSciences: Integra LifeSciences is a diversified medical device company with regenerative tissue technologies (Integra dermal regeneration templates) and ophthalmology exposure, representing a much larger incumbent that could enter adjacent amniotic membrane segments.
• Bausch + Lomb: Bausch + Lomb is a global ophthalmology leader offering a broad portfolio of surgical, vision care, and pharmaceutical products; relevant as a broad incumbent whose scale and distribution could threaten niche players like NuVision if it enters amniotic membrane therapeutics.

Regional players

• Seed Biotech (Japan): Seed Biotech develops amniotic membrane-related ophthalmic products in Japan, comparable as a regional amniotic membrane player serving the Japanese market with similar clinical indications to NuVision's Omnigen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/NuVisBio
• YouTubeyoutube.com/channel/UCUY4I95j5sZptMf9bhY-0wA
• Facebookfacebook.com/674628089256475
• LinkedInlinkedin.com/company/nuvision-ophthalmics-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NuVision